Why did management walk back the FY27 guidance?

They cited macro uncertainty and declined to reaffirm the previously stated FY27 EBITDA (18-20%) and PAT margin (13-15%) targets during the Q4 call.

How far did FY26 PAT margin miss its target?

The full-year PAT margin was 10.4%, well below the 13-15% guidance range provided in earlier calls.

What was the strongest part of the Q4 result?

Revenue hit a record ₹74 cr, and the EBITDA margin was 18.3%. The quarter also saw US tariff relief and the launch of the iScope 360 platform.

What is the iScope 360 platform?

It's a new remote dentistry platform launched in Q4, aimed at expanding the company's digital capabilities.

How does the US tariff change help the business?

The tariff reduction from 50% to 10% on exports to the US should improve margins for that segment of Laxmi Dental's business.

When might we get clarity on the new guidance?

Management has not committed to providing new targets. The Q1 FY27 earnings call is the next opportunity for an update.

Concalls · Medical Equipment · Small cap

Laxmi Dental hits record revenue, then pulls FY27 guidance

A strong Q4 was immediately overshadowed by management's refusal to reaffirm profit targets, after missing FY26 margin guidance.

— 3 earlier stories on Laxmi Dental Ltd. →

LAXMIDENTL By Tipsheet Editorial 22 May 2026 · 11:04 AM IST Verify on BSE · NSE

Mkt cap₹1,229 cr

P/E42.41×

ROE15.24%

Debt / eq.0.05

10.4% FY26 PAT margin, missed the 13-15% guidance.

What's new

Record Q4 revenue of ₹74 cr and EBITDA margin of 18.3%.
Management refused to reaffirm FY27 EBITDA (18-20%) and PAT margin (13-15%) targets, citing macro uncertainty.
FY26 PAT margin of 10.4% fell short of the 13-15% guidance given in prior calls.

Why this matters

A record quarter is immediately overshadowed by a guidance retreat. Management missed its own FY26 profit target, then refused to commit to FY27 numbers. That sequence erodes credibility more than a single earnings miss would.

What we're watching

Whether management reissues guidance in the Q1 FY27 call.
Impact of US tariff normalization from 50% to 10% on export margins.
Adoption ramp for the new iScope 360 remote dentistry platform.

The full read

Laxmi Dental's Q4 was its best ever: ₹74 cr revenue, 18.3% EBITDA margin. The quarter also brought US tariff relief, from 50% to 10%, and the launch of the iScope 360 platform. The numbers are good. The guidance is not. Management refused to reaffirm FY27 targets. They walked back the previously stated EBITDA margin of 18-20% and PAT margin of 13-15%, citing macro uncertainty. This comes after a FY26 PAT margin of 10.4% – well below the 13-15% band flagged earlier. A record quarter doesn't fix a guidance miss. The open question is how long management stays silent. A single quarter of outperformance, followed by a guidance retreat, forces a recalibration of trust.

Questions answered

Why did management walk back the FY27 guidance?: They cited macro uncertainty and declined to reaffirm the previously stated FY27 EBITDA (18-20%) and PAT margin (13-15%) targets during the Q4 call.
How far did FY26 PAT margin miss its target?: The full-year PAT margin was 10.4%, well below the 13-15% guidance range provided in earlier calls.
What was the strongest part of the Q4 result?: Revenue hit a record ₹74 cr, and the EBITDA margin was 18.3%. The quarter also saw US tariff relief and the launch of the iScope 360 platform.
What is the iScope 360 platform?: It's a new remote dentistry platform launched in Q4, aimed at expanding the company's digital capabilities.
How does the US tariff change help the business?: The tariff reduction from 50% to 10% on exports to the US should improve margins for that segment of Laxmi Dental's business.
When might we get clarity on the new guidance?: Management has not committed to providing new targets. The Q1 FY27 earnings call is the next opportunity for an update.

Mentioned: Laxmi Dental · iScope 360 · ₹74 cr revenue

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Laxmi Dental Ltd.

Pharmaceuticals

₹1,238 cr

P/E 42.73×

Latest quarter · Mar 2026

Sales₹74 cr

Net profit₹11 cr

Op. margin+18.3%

EPS₹1.83

Strength & growth

Debt / equity0.05×

Current ratio3.30×

Story so far

All notes on LAXMIDENTL →

22 May 2026 · 11:04 AM IST Laxmi Dental hits record revenue, then pulls FY27 guidance
41d ago Laxmi Dental record revenue, but no new margin target for FY27
50d ago Laxmi Dental re-announces audited Q4 and FY26 results it already filed.
50d ago Laxmi Dental posts 22% revenue growth, but a new labour-law charge hits profit